SCHEMBL20424901

SCHEMBL20424901

CCOc1ccccc1/C=C(\CC)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.50
GLA P06280 1/20 0.50
PTGES O14684 2/20 0.48
ALOX5 P09917 2/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 2/20 0.46
PKM P14618 1/20 0.46
PLIN1 O60240 1/20 0.46
POLB P06746 1/20 0.46
PLIN5 Q00G26 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28893878 1.00 KDM4E (0.58) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL2288436 0.87 KMT2A (0.46) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL7825926 0.86 KMT2A (0.61) KDM4EKMT2AMEN1PTGESALOX5
SCHEMBL7825925 0.86 KMT2A (0.61) KDM4EKMT2AMEN1PTGESALOX5
SCHEMBL24611347 0.85 LMNA (0.57) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL28330434 0.85 LMNA (0.57) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL4739417 0.84 KDM4E (0.57) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL11828120 0.83 KDM4E (0.56) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL9789045 0.81 KDM4E (0.78) KDM4EKMT2AMEN1CYP1A2CYP2C9
SCHEMBL9789047 0.81 KDM4E (0.78) KDM4EKMT2AMEN1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710181-A Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2023-02-24 CN disclosed
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2022-12-01 US disclosed
CN-110494413-B Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2022-11-22 CN disclosed
EP-4059917-A2 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF ChemCom S.A. (BE) 2022-09-21 EP disclosed
US-11382848-B2 Compounds reducing malodour perception and the use thereof CHEMCOM S.A. (BE) 2022-07-12 US disclosed
EP-3573944-B1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM SA (BE) 2022-03-02 EP disclosed
WO-2018138369-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2018-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11382848-B2 Compounds reducing malodour perception and the use thereof OR51E2, OR10J3, SRD5A1 KDM4E 3128/4885KMT2A 4460/4885MEN1 1364/4885
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF OR51E2, OR10J3, SRD5A1 KDM4E 3128/4885KMT2A 4460/4885MEN1 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.